Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
Status:
Active, not recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Hot flashes present a considerable problem for many breast cancer patients; these symptoms
may be intensified by hormonal therapies, such as aromatase inhibitors or tamoxifen. This
study examines the value of solifenacin (a muscarinic acetylcholine receptor antagonist) in
reducing hot flashes, compared with clonidine (a medication often used for treating hot
flashes).